All News

colitis.jpg

No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients

Jack Cush, MD

UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse cardiovascular events (MACE) in JAKi vs TNFi use in IBD.

Read Article
obese.waist_.jpg

Weight Loss from Anti-Obesity Medications Prevents Gout

Jack Cush, MD

A population based study looked at the effect of the weight loss drug, Orlistat, in obese individuals. Compared to those untreated, orlistat over 1 year was associated with significant weight loss and significantly lower risks of incident gout and recurrent gout flares among overweight or obese people.

Read Article
biosimilars2.jpg

Biosimilar Slow Growth in USA

Jack Cush, MD

A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.

Read Article
Liver.hepatitis.jpg

Advances in the treatment of autoimmune hepatitis

EurekAlert!

Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure. 

Read Article
Cutaneous.lupus.SLE.Face.dermnetnz

Iberdomide Efficacy in Cutaneous Lupus

Jack Cush, MD

Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).

Read Article
AMA report says..... " More than one in three physicians, 34 percent, have had a medical liability lawsuit filed against them at some point in their careers" - Nearly half of physicians >55 have been sued (vs 6% in MDs <40yrs) - Female physicians are less likely to be sued than… https://t.co/hIUH7Tx85L https://t.co/V2sHyac3XH
Dr. John Cush RheumNow ( View Tweet)
Systematic review suggests (although not provn) that audiovestibular dysfunction may be from APS. Anti-phospholipid & HSP-70 Abs found 25-33% w/idiopathic sudden sensorineural hearing loss,. ACL Abs seen in up to 27% w/ sensorineural hearing loss https://t.co/GTcLoM0SCZ https://t.co/afFntYnPPG

Links:

Dr. John Cush RheumNow ( View Tweet)
Early Rx doesnt prevent Difficult to Tx RA (D2TRA). Propective study of 722 early RA pts Rx w/ MTX found after 73 mos 29% were D2TRA. 21.5% Rx w/ b/tsDMARD after 19 mos, yet 70% were uncontrolled. 5 yr retention rates were 40%. D2T predicted by pain & swollen joints… https://t.co/veaspuCHIE https://t.co/zjlTWQn4GQ
Dr. John Cush RheumNow ( View Tweet)
Peptic ulcer disease is still assoc w/ signif. hospitalization & mortality (10K deaths in USA/Yr). PUD affects 10% of outpts w/ Upper GI pain. 42% are due to H.pylori, 36% from ASA NSAIDs. Complications bleeding (73%), perforation (9%), pyloric obstruction (3%)- JAMA review… https://t.co/1bgagFVlYN https://t.co/8i2j3r1puf
Dr. John Cush RheumNow ( View Tweet)
Korean database of 43,502 #AS pts found CV events based on Rx exposure. CV event rates were: No bDMARDS (18.66/10K PYs), TNFi (8.92), & IL-17i (12.87). TNFi significantly lowered rate of CVE (aHR 0.69), but IL-17i did not (0.96) https://t.co/LMzPodWI5v https://t.co/rQ0aq1ALgW

Links:

Dr. John Cush RheumNow ( View Tweet)
Genes Linking RA and Osteoporosis People with rheumatoid arthritis often develop osteoporosis, a more serious condition, as a result of the bone damage caused by immune cells and as a side effect of certain medications. https://t.co/hEJc77gcln https://t.co/bmsV70riUc

Links:

Dr. John Cush RheumNow ( View Tweet)
Taiwan claims data study of 135 230 patients who received antineoplastic medications, found that immune checkpoint inhibitors use was associated with a 2-fold increased risk of developing psoriasis (HR 2.43). https://t.co/m5eGT56W12 https://t.co/h5FjQpHOpF

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush RheumNow ( View Tweet)
Survey of UK Rheumatology pts (n 876 found 55% take daily supplements costing £10 to £200 per month (most common: vit D, C, B complex, MVI Omega 3/6). 82% take Prescription, OTC, or non-prescription pain meds, 13% sleep aids. Half of NSAID pts also take OTC supplements… https://t.co/VpMG9SiE1E https://t.co/SJYUfogeVJ
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 26 RCTs suggests JAK inhibitors have a low, but signif. increased risk of infections (vs placebo) (RR 1.39; 1.096-1.76). No risk of tuberculosis or hepatitis, but an incr. risk of H. zoster was seen (RR 1.71; 0.84-3.51) https://t.co/kXOcldz46l https://t.co/Y5OWk4W1NZ

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA's perspective on the use of artificial intelligence in drug development. - FDA is committed to a risk-based regulatory framework that promotes innovation & protects Pt safety - Est. CDER AI Council to coordinate, develop, & support internal & external AI-related activities… https://t.co/BLCYmBBJMY https://t.co/fMie3oOfmn
Dr. John Cush RheumNow ( View Tweet)
An 11 yr study of 2187 #RA pts Rx w/ 3068 treatment courses of biologics or JAki, found 275 new cases of #CKD . Compared w/ CTLA4-Ig, TNFi significantly lower CKD rates (HR 0.67), whiile JAKi higher CKD rates (HR 2.16). https://t.co/2Y5BuDzJRs https://t.co/e81lOhOMjX

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm
Dr. John Cush RheumNow ( View Tweet)
Are seronegative RA and clinically suspect arthralgia pts represented in randomized clinical trials? Most RCTs (And prevention trials) predominantly enroll seropositive patients. - potentially overlooking seronegative individuals with arthralgia-at-risk. https://t.co/D1eOApgn1p https://t.co/IBCNtNW8uI

Links:

Dr. John Cush RheumNow ( View Tweet)
Filgotinib Efficacy and Safety - 3 Years Later Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in… https://t.co/eABIG1Kal6 https://t.co/7ZphZALniE
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×